CordenPharma completes API process bay for category 4 compounds

By Melissa Fassbender contact

- Last updated on GMT

CordenPharma Colorado's new highly potent API process bay. (Image: CordenPharma)
CordenPharma Colorado's new highly potent API process bay. (Image: CordenPharma)

Related tags: United states

This week CordenPharma announced the completion of its new highly potent API process bay for category 4 compounds.

The addition was completed at the company’s Boulder, Colorado facility, which is equipped to handle highly potent compounds up to OEB Level 5 spanning development to commercial-scale.

With the new process bay, the facility can now handle a range of chemistries and unit operations with flexible and scalable components up to multi-kg batches.

(Image: CordenPharma)
(Image: CordenPharma)

According to Brian McCudden, President and Managing Director of CordenPharma Colorado, the first cGMP campaign is scheduled to be completed in early Q4 2016.

The investment comes on the heels of several facility improvements, including expanded development capabilities (CTD2) at its Plankstadt (Germany) facility, and further expansion of capabilities in handling sterile oncology drug products at CordenPharma Latina (Italy).

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars